DNTH vs KNSA
DNTH: Dianthus Therapeutics is a clinical-stage biopharmaceutical company developing targeted complement-pathway inhibitors to treat severe autoimmune and inflammatory diseases. KNSA: Kiniksa is a biopharmaceutical company developing and commercializing therapies for chronic inflammatory and autoimmune diseases, with a pipeline featuring novel treatments for recurrent pericarditis.
Side-by-side fundamentals
| Metric | DNTH | KNSA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $104.49 | $74.34 | |
| Market cap as of 2026-08-03 | $5.7B | $5.8B | |
| P/E as of 2026-08-03 | n/a | 75.64 | |
| PEG as of 2026-08-03 | -0.63 | 0.03 | DNTH lower |
| Net margin as of 2026-08-03 | -12998.5% | +9.6% | KNSA higher |
| Gross margin as of 2026-08-03 | n/a | +89.8% | |
| Operating margin as of 2026-08-03 | -14318.0% | +11.9% | KNSA higher |
| ROE as of 2026-08-03 | -27.3% | +13.7% | KNSA higher |
| ROA as of 2026-08-03 | -25.9% | +10.1% | KNSA higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-03 | -79.5% | +58.9% | KNSA higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +45.5% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-08-03 | 1.75 | 0.50 | |
| 1-year return as of 2026-07-27 close | +386.0% | +145.7% | DNTH higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.